- PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated? Czech atherosclerosis society statement2016 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Indication of PCSK9 inhibitors in the expert view of the CSAT2016 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Ezetimibe and combination of lipid lowering medications: what is their role in the era of PCSK9 inhibitors?2017 | First Faculty of Medicine
- PCSK9 inhibitors in light of recent data2016 | First Faculty of Medicine
- PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology2022 | First Faculty of Medicine
- New possibilities of dyslipidemiaa therapy in patients with familial hypercholesterolemia in secondary prevention - change in reimbursement for PCSK9 inhibitors2021 | First Faculty of Medicine
- The treatment of hypercholesterolemia by PCSK9 inhibitors2014 | Faculty of Medicine in Hradec Králové
- PCSK9 inhibitor evolocumab in the FOURIER outcomes trial2017 | First Faculty of Medicine
- Turn in hypercholesterolemia treatment - PCSK9 inhibitors. What we know about the alirocumab (product Praluent(R)) yet?2016 | First Faculty of Medicine
- Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial2019 | First Faculty of Medicine
- First impressions of the ODYSSEY Outcomes trial2018 | First Faculty of Medicine
- Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial2017 | First Faculty of Medicine
- Lipid lowering therapy - proven treatment options and prospects for the near future2022 | First Faculty of Medicine
- Coronary atherosclerosis regression - theory, facts and clinical relevance2016 | Faculty of Medicine in Hradec Králové
- Evolocumab, proproteine convertase subtilisin/kexin type 9 inhibitor for intensive treatment of dyslipidemia2016 | Faculty of Medicine in Pilsen
- Does "LDL hypothesis" also apply to patients with diabetes?2015 | Second Faculty of Medicine
- News in cardiovascular prevention: from guidelines to novel treatment options2015 | First Faculty of Medicine
- Alirocumab, human monoclonal antibody in biological dyslipidemia treatment2016 | Faculty of Medicine in Pilsen
- Severe familial hypercholesterolemia treatment2016 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Treatment of dyslipidemias - questionaires, and the future2016 | First Faculty of Medicine
- Long-Term LDL-Apheresis Treatment and Dynamics of Circulating miRNAs in Patients with Severe Familial Hypercholesterolemia2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- How deep is LDL cholesterol fall?2014 | First Faculty of Medicine
- How to deal ugly twins, LDL-cholesterol and lipoprotein (a)2016 | Second Faculty of Medicine
- Regression of coronary atherosclerosis in light of recent studies2019 | First Faculty of Medicine, Central Library of Charles University
- A near future of treatment of dyslipidemia in type 2 diabetics2016 | First Faculty of Medicine
- News in the treatment of dyslipidaemia2019 | First Faculty of Medicine
- Current and future trends in the treatment of dyslipidemias2019 | First Faculty of Medicine
- Repatha - evolocumab, first in Europe registered inhibitors PCSK2015 | First Faculty of Medicine
- Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)2021 | First Faculty of Medicine